Key result
Novel biomarkers such as galectin-3, adiponectin, and irisin show significant changes during the clinical course of diabetic cardiomyopathy and may aid in its early diagnosis and management.
Why the study?
Most existing clinical markers lack specificity for diabetic cardiomyopathy, particularly in its early asymptomatic stages when tissue damage begins, necessitating research on biomarkers for early diagnosis and management.
Novel biomarkers such as adiponectin, irisin, and galectin-3 show promise for the early diagnosis and targeted treatment of diabetic cardiomyopathy before irreversible structural damage occurs.
Biomarker research for early DCM detection remains essential; leaves open impact on mortality in asymptomatic diabetics.
Diabetic cardiomyopathy (DCM) is a serious cardiovascular complication and the leading cause of death in diabetic patients. Patients typically do not experience any symptoms and have normal systolic and diastolic cardiac functions in the early stages of DCM. Because the majority of cardiac tissue has already been destroyed by the time DCM is detected, research must be conducted on biomarkers for early DCM, early diagnosis of DCM patients, and early symptomatic management to minimize mortality rates among DCM patients. Most of the existing implemented clinical markers are not very specific for DCM, especially in the early stages of DCM. Recent studies have shown that a number of new novel markers, such as galactin-3 (Gal-3), adiponectin (APN), and irisin, have significant changes in the clinical course of the various stages of DCM, suggesting that we may have a positive effect on the identification of DCM. As a summary of the current state of knowledge regarding DCM biomarkers, this review aims to inspire new ideas for identifying clinical markers and related pathophysiologic mechanisms that could be used in the early diagnosis and treatment of DCM.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2023) conducted a review in Diabetic cardiomyopathy. Biomarkers (e.g., galectin-3, adiponectin, irisin) was evaluated. Novel biomarkers such as galectin-3, adiponectin, and irisin show significant changes during the clinical course of diabetic cardiomyopathy and may aid in its early diagnosis and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: